Iamotrigine monotherapy overpowers carbamazepine in post stroke epilepsy
Patients with Poststroke Epilepsy receiving lamotrigine monotherapy had significantly lower mortality compared with those receiving carbamazepine, according to a recent study published in the JAMA Neurology.
There is little evidence to guide the choice of antiseizure medication (ASM) for patients with poststroke epilepsy. Theoretical concerns about the detrimental effects of ASMs on survival exist. Enzyme-inducing drugs could interfere with secondary stroke prevention. The US Food and Drug Administration recently issued a safety announcement about the potential proarrhythmic properties of lamotrigine. A group of researchers conducted a study to investigate whether mortality varies with specific ASMs among patients with poststroke epilepsy.
For more information check out the link below:
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)